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sUmmARy –Recurrent stroke is a major cause of morbidity and mortality among stroke survi-
vors.  With improved survival after first ischemic stroke, stroke recurrence may account for a greater 
share of the future annual cost of stroke-related health care. despite advances in stroke prevention 
strategies and treatments, stroke recurrence is still the major threat to any stroke survivor. This re-
view discusses antithrombotic therapy in secondary stroke prevention which has a major impact in 
clinical practice. 
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Introduction
stroke is the third leading cause of death and the 
main cause of disability in the United states1. About 
15% to 26% of all strokes are preceded by a transient 
ischemic attack (tiA)2, and the risk of stroke after 
tiA or minor stroke is 8.4%3 to 10% at 3 months4. 
Although traditionally a distinction has been made 
between tiA and stroke, magnetic resonance imag-
ing data have shown that many individuals with tiA, 
particularly after prolonged events, have imaging evi-
dence of cerebral infarction5. Therefore, the approach 
to secondary prevention after stroke or tiA is similar. 
This brief review mentions recent studies using anti-
thrombotic therapy that impact clinical practice.  it is 
not meant to provide an exhaustive review of current 
recommendations for secondary ischemic stroke pre-
vention because these have been delineated in recent 
guidelines6-8. 
Antithrombotic agents in stroke prevention include 
anticoagulants and antiplatelet agents. Antiplatelet 
agents are reserved for patients with non-cardioem-
bolic stroke, such as large- or small-vessel-related 
strokes. Recent studies have contributed to the exten-
sive literature on the role of antithrombotic therapy in 
secondary stroke prevention. Anticoagulants are pre-
scribed for cardioembolic strokes, venous strokes, and 
strokes such as related to dissection.
Non-Cardioembolic Strokes
The antiplatelet agents, aspirin (50-325 mg/day), 
aspirin plus extended release dipyridamole, and clopi-
dogrel monotherapy, are all acceptable options in 
secondary prevention of strokes of arterial origin9. 
A recent update to existing recommendations states 
that the combination of aspirin and extended-release 
dipyridamole is recommended over aspirin alone, and 
that clopidogrel may be considered over aspirin alone8. 
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studies that support the use of these agents have been 
extensively reviewed6-8. other individual antiplatelet 
agents have been evaluated or are in testing. triflusal, 
a compound structurally related to aspirin, was found 
to have a similar effect as aspirin on the combined end 
point of stroke, myocardial infarction, and vascular 
death, but with less hemorrhagic complications; how-
ever, it is not available in the United states10,11. A novel 
thienopyridine, prasugrel, has been studied in patients 
with acute coronary syndromes; when compared with 
clopidogrel, it resulted in a reduction in myocardial 
infarction, stroke, and cardiovascular death, at the ex-
pense of a slight increase in hemorrhagic risk12. other 
agents such as thrombin receptor antagonists are being 
tested; in the current tRA2p-timi 50 trial (http://
clinicaltrials.gov), one such agent is being tested in 
addition to standard antiplatelet agents in prevention 
of coronary and cerebrovascular outcomes.
given the limited effects of single antiplatelet 
agents, there has been an interest in combination 
therapy. The espRit (european/Australasian stroke 
prevention in Reversible ischaemia trial) study13, 
which was published after the 2006 American heart 
Association recommendations, compared aspirin plus 
extended release dipyridamole and aspirin alone and 
found an hazard ratio (hR) of 0.8 (95% Ci, 0.66-0.98) 
for the combined end point of stroke, myocardial in-
farction, vascular death, and major hemorrhage for the 
combination; the hR for stroke alone was 0.84 (95% 
Ci, 0.67-1.17). This study was limited by the open 
treatment assignment (although outcome evaluation 
was blinded), the nonstandard aspirin dose, and dis-
crepancy between the intention-to-treat and on-treat-
ment analysis. nonetheless, these results validate the 
findings of the european stroke prevention study 214. 
direct comparison of clopidogrel versus aspirin plus 
extended-release dipyridamole in the pRoFess study 
has recently demonstrated that the risks of recurrent 
stroke or the composite of stroke, myocardial infarc-
tion, or vascular death are similar with both regimens 
15. however, increased risks of nonfatal hemorrhagic 
stroke and side effects leading to discontinuation of 
therapy were significantly often seen with aspirin plus 
extended-release dipyridamole. 
The combination of aspirin and clopidogrel has 
been utilized in the coronary arteries successfully. 
nonetheless, in stroke prevention, this combination 
has not shown greater efficacy than clopidogrel alone 
and resulted in greater hemorrhagic risk16. The ChA-
RismA (Clopidogrel for high Atherothrombotic 
Risk and ischemic stabilization, management and 
Avoidance) study17 evaluated patients with cerebro-
vascular disease, coronary disease, peripheral vascular 
disease, or multiple vascular risk factors, who were ran-
domized to receive aspirin or aspirin plus clopidogrel. 
There was no statistically significant reduction in the 
primary combined end point of stroke, myocardial in-
farction, and vascular death (relative risk, 0.93; 95% 
Ci, 0.83-1.05), or of nonfatal ischemic stroke (relative 
risk, 0.81; 95% Ci, 0.64-1.02). Combination therapy 
resulted in a greater incidence of bleeding than with 
aspirin alone (severe bleeding: 1.7% combination, 
1.3% aspirin; P = 0.09; moderate bleeding: 2.1% com-
bination, 1.3% aspirin; P < 0.001). These data rein-
force prior experience showing lack of efficacy of the 
combination of aspirin and clopidogrel for secondary 
stroke prevention16. At this point, evidence suggests 
that the combination of aspirin and clopidogrel is 
not superior to either agent alone in secondary stroke 
prevention and results in a greater frequency of hem-
orrhages. ongoing studies will further contribute to 
the understanding of the role of combination aspirin 
and clopidogrel in stroke reduction. The sps3 study 
is currently evaluating aspirin 325 mg plus clopidogrel 
75 versus aspirin 325 mg alone in preventing stroke re-
currence in patients with small subcortical infarcts18. 
The ARCh (Aortic Arch Related Cerebral hazard) 
study (http://clinicaltrials.gov) is comparing the com-
bination of aspirin and clopidogrel versus warfarin in 
preventing stroke and systemic embolism in patients 
with aortoembolic stroke.
because the risk of stroke after an initial cerebro-
vascular ischemic event is greatest in the first few days 
and weeks, particularly with large-vessel disease19, it 
is worthwhile to discuss early and acute prophylaxis 
with antithrombotic agents. Although this should 
be individualized according to the mechanism of the 
event, studies have provided important guidelines. 
earlier studies20,21 showed a small benefit of early 
initiation of aspirin. The combination of aspirin and 
clopidogrel reduced the presence of microembolic 
signals in those with recently symptomatic carotid 
stenosis22. Recently, the FAsteR trial4 randomized 
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patients within 24 hours of their ischemic event to as-
pirin or aspirin plus clopidogrel. This small study was 
stopped early and found a nonstatistically significant 
reduction in the 90-day risk of stroke for combination 
antiplatelet therapy. Therefore, the use of combination 
antithrombotic agents in the acute period for a limited 
time should be further explored in randomized trials, 
but as yet, there is no definite indication to modify 
existent recommendations.
Intracranial Stenosis
The WAsid study24 evaluated patients with a 
recent stroke or tiA caused by intracranial arterial 
disease of 50% to 99% and randomized participants 
to aspirin 1,300 mg/day versus warfarin international 
normalized ratio 2 to 3. The study was terminated be-
cause of a safety concern. There was no difference in 
the primary outcome of ischemic stroke, intracerebral 
hemorrhage, or vascular death between the two treat-
ment arms, which occurred at a staggering 22% dur-
ing the 1.8-year average follow-up period. most of the 
events occurred in the first couple of weeks. however, 
there was a greater than twofold incidence of major 
hemorrhage or death in the anticoagulated group. 
There was no subgroup of patients in whom warfarin 
was superior to aspirin24. Consequently, warfarin ap-
pears to be no more effective and riskier than aspirin 
for this disease. This study also allowed the identi-
fication of a group at a high risk of recurrent stroke 
in the territory of the stenotic vessel, including those 
with a severe stenosis (70%-99%), women, and enrol-
ment soon after the onset of symptoms25. Therefore, 
an individual presenting with a stroke caused by a 
70% to 99% intracranial stenosis would have a 2-year 
risk of recurrent stroke of 25%, whereas a lower de-
gree of stenosis of 50% to 69% would carry only an 
11% risk25.
given the increased risk of recurrence, there 
has been considerable interest in endovascular ap-
proaches to intracranial stenosis. initial experience 
with balloon-expandable stents was associated with 
a high risk of periprocedural complications26, but the 
development of self-deployed stents appears to pro-
vide a safer alternative27. The efficacy of endovascular 
therapy against best medical therapy will be studied 
in an upcoming study; the sAmmpRis (stenting 
and Aggressive medical management for preventing 
stroke in intracranial stenosis) study (http://clinical-
trials.gov) will evaluate best medical therapy, includ-
ing antiplatelet therapy, aggressive LdL reduction, 
and tight blood pressure control, versus endovascular 
therapy with self-deployed stents in patients with a 
recently symptomatic intracranial stenosis of 70% to 
99%. however, currently, the author believe that in-
tracranial stenting outside a clinical trial should be 
reserved for those high risk patients who have had re-
current events on medical therapy.
Cardioembolic Stroke
Atrial fibrillation (AF) remains a prominent cause 
of ischemic stroke worldwide. The incidence of AF in-
creases with age and prevalence reaches 10% in octo-
genarians28.  The proportion of strokes attributable to 
this common arrhythmia will continue to rise as our 
population ages. in the Framingham study, almost 
one fourth of all strokes that occurred in patients aged 
>80 years were attributable to AF29. given our aging 
population, it is estimated that by the year 2050, there 
may be as many as 10 million individuals with atrial 
fibrillation in this country30. many studies have con-
firmed the superiority of anticoagulants over placebo 
and antiplatelet agents in atrial fibrillation. A recent 
meta-analysis of more than 28,000 subjects31 con-
cluded that warfarin reduced the relative risk of stroke 
by 64% (95% Ci, 49-74%) compared with placebo, 
whereas antiplatelet agents reduced the risk by 22% 
(6%-35%). direct comparison of anticoagulants versus 
antiplatelet agent showed a 39% (22%-52%) relative 
risk reduction in favor of warfarin. The risk of in-
tracranial hemorrhage with warfarin compared with 
aspirin was small, with an absolute increase of 0.2% 
per year. Therefore, current guidelines recommend ad-
justed dose warfarin (target international normalized 
ratio, 2.5; range, 2-3) for stroke prevention in AF6,7.
nonetheless, the use of warfarin is burdensome 
because its bioeffects are variable and there is the 
need for frequent blood testing. This has led to a 
growing interest in direct thrombin inhibitors, which 
offer stable dosing, few interactions with other medi-
cations, no dietary restrictions, and no need for in-
ternational normalized ratio testing. Ximelagatran 
was evaluated in recent studies32 and found to be as 
effective as warfarin in preventing recurrent strokes 
(2.83%/ year with ximelagatran and 3.27%/year with 
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warfarin; P = 0.625), with similar rates for hemor-
rhagic complications. however, 6% of those treated 
with ximelagatran had a significant increase in liver 
enzymes; therefore, this agent was not approved by 
the FdA for secondary stroke prevention. Another 
direct thrombin inhibitor, dabigatran, has currently 
been tested in Randomized evaluation of Long-term 
Anticoagulant Therapy (Re-Ly) trial33. Results of 
Re-Ly indicate that warfarin’s supremacy for stroke 
prevention in AF is in jeopardy. Re-Ly is the largest 
stroke prevention trial in patients with AF ever un-
dertaken; over 18 000 patients with AF and at least 1 
additional vascular risk factor were randomized to re-
ceive 1 or 2 doses of dabigatran or dose-adjusted war-
farin. Like ximelagatran, dabigatran etexilate (a prod-
rug of the active moiety dabigatran) is another direct 
thrombin inhibitor. dabigatran is already approved 
in europe and Canada for the prevention of venous 
thromboembolism after hip and knee replacement 
surgery. because dabigatran leads to a predictable level 
of anticoagulation with a low potential for drug-drug 
or food interactions, blood monitoring is unnecessary. 
There is an interaction with amiodarone, however, an 
important consideration in the AF population.
Another common cause of cardioembolism is 
cardiac failure and reduced ejection fraction. how-
ever, little research has been done in antithrombotic 
therapy of this population. The ongoing WARCeF 
(Warfarin-Aspirin Reduced Cardiac ejection Frac-
tion) study is evaluating the effects of aspirin versus 
warfarin in patients with reduced ejection fraction 
(<35%) in preventing stroke and death34.
Conclusion
The role of antithrombotic agents in secondary 
stroke prevention is of major significance. new direct 
and indirect thrombin inhibitors show great prom-
ise in prevention of subsequent stroke. There are still 
many unanswered questions that will be addressed by 
ongoing randomized trials that are likely to change 
the future practice to reduce stroke recurrence.
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sažetak
Antibiotski LiJekovi U sekUndARnoJ pRevenCiJi moŽdAnog UdARA
T. Rundek, V. Bašić-Kes, S. Morović i V. Demarin
ponavljajući moždani udar je najčešći uzrok pobola i smrtnosti među preživjelima nakon moždanog udara. Uz veće 
preživljavanje nakon prvog ishemijskog moždanog udara, ponavljajući moždani udari zauzimaju velik dio nadolazećih go-
dišnjih izdataka vezanih za zbrinjavanje moždanog udara. Usprkos napretku strategija za prevenciju i liječenje moždanog 
udara ponovni moždani udar je najopasnija prijetnja bilo kome tko je preživio moždani udar. ovaj pregledni članak posve-
ćen je antitrombotskoj terapiji u sekundarnoj prevenciji moždanog udara, gdje ima najznačajniji utjecaj u kliničkoj praksi.
ključne riječi: Moždani udar, sekundarna prevencija; Trombociti, agregacija, inhibitori – terapijska primjena; Antikoagu-
lansi
